Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 8, Pages 4511-4515Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.06449-11
Keywords
-
Categories
Funding
- Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (Madrid, Spain)
- Spanish Network for Research in Infectious Diseases [REIPI RD06/0008]
- Fondo de Investigaciones Sanitarias (FIS
- Madrid, Spain) [FIS 080268, FIS 1101131]
- Fundacion Maximo Soriano Jimenez (Barcelona, Spain)
- Instituto de Salud Carlos III (Madrid, Spain)
- Departament de Salut de la Generalitat de Catalunya, Barcelona (Spain)
- Agencia Pedro Lain Entralgo (Madrid, Spain)
- Abbott
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Cubist
- Novartis
- GlaxoSmithKline
- Gilead Sciences
- Pfizer
- Roche
- Theravance
- Fundacion Carolina-BBVA (Madrid, Spain)
Ask authors/readers for more resources
We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11(79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
